THE APEX TIMES
Late-breaking Phase 4 data from the STAR study are being positioned by Johnson & Johnson as evidence that its psoriasis drug TREMFYA (guselkumab) can improve spinal pain and stiffness in biologic-naïve adults with axial psoriatic arthritis, including MRI-confirmed measures.
Johnson & Johnson is drawing attention to late-breaking clinical results for TREMFYA (guselkumab) in psoriatic arthritis, using imaging findings to support the drug’s potential impact on axial disease, which affects the spine and can be particularly difficult to treat. In a post circulated by Yahoo Finance, the company said it presented data from a Phase 4 study known as STAR in biologic-naïve adults with active psoriatic arthritis and axial involvement, sometimes described as axial PsA.
TREMFYA is an injection approved for certain immune-mediated conditions, including plaque psoriasis. In the STAR study update, Johnson & Johnson said TREMFYA demonstrated MRI-confirmed improvements tied to spinal pain and stiffness, according to the announcement carried in the market news report.
The company’s framing in the release is also comparative. Johnson & Johnson said the results make TREMFYA the only advanced therapy to show MRI-confirmed improvements in spinal pain and stiffness in this setting, based on the way the study findings were characterized in the cited report. The claim centers on MRI-confirmed changes, which are typically used in axial spondyloarthritis and related disorders to track structural and inflammatory activity beyond patient-reported symptoms.
The trial, described as Phase 4, focuses on real-world treatment questions that go beyond earlier studies, including how a medicine performs in specific patient populations and disease subtypes. Here, the STAR data were reported for adults who were biologic-naïve, meaning they had not previously been treated with biologic therapies that target specific parts of the immune system.
While Johnson & Johnson highlighted improvements on imaging and symptoms, the market news report did not provide additional technical details in the text available for this editorial review, such as the exact MRI scoring system used, the size and duration of the study arms, or the magnitude of changes. It also did not lay out the comparator therapies referenced in the “only advanced therapy” statement.
Still, the company’s emphasis aligns with how axial psoriatic arthritis is evaluated in late-stage and post-approval research. Patients often experience pain and stiffness that can reflect ongoing inflammation, and MRI can detect that activity in the spine. If the findings hold up in the full dataset and any accompanying conference materials, they could strengthen the rationale for targeting axial disease with an IL-23 pathway approach.
For Johnson & Johnson’s broader oncology-adjacent and immunology portfolio, the update underscores the competitive importance of expanding indications within immune-mediated diseases and distinguishing therapies based on measurable disease activity. The axial PsA market has been a focal point for drug developers because unmet need remains for durable symptom control alongside objective evidence of reduced inflammation.
What is not clear from the available report text is whether the MRI findings translated into consistent improvements across all clinical endpoints, and whether any safety indicates emerged during the reported period. For readers tracking the development, the next checkpoint will be whatever additional disclosures Johnson & Johnson and the trial organizers provide, such as the full set of efficacy endpoints, imaging methodology, and safety summaries associated with the STAR presentation.
A reported Phase 3 win for Moderna’s personalized melanoma therapy, used alongside Merck’s Keytruda, is prompting fresh optimism that the mRNA platform can expand beyond infectious disease. Still, key details such as magnitude of benefit and full trial disclosure remain to be validated.
The company is pursuing Australian National Immunisation Program listings for its mRNA influenza vaccines after securing a March 2027 agenda spot with the PBAC, a key committee that advises public reimbursement.
The initiative, launched within Aetna, is designed to link a large share of expectant members and their newborns to coordinated maternal and infant care. CVS Health has not, in the reporting, disclosed staffing, clinical protocols, or outcome targets tied to the program.
A recent analyst upgrade focus shifted toward profitability drivers inside Medicare Advantage and the operational momentum of Optum Health, as well as what the bank characterizes as disciplined pricing.
Comments
Community guidelines. Comments may be removed for violations.
Loading comments...